Pharmaceutical Marketing Quotes

The current ruling ontology denies any possibility of a social causation of mental illness. The chemico-biologization of mental illness is of course strictly commensurate with its depoliticization. Considering mental illness an individual chemico-biological problem has enormous benefits for capitalism. First, it reinforces Capital’s drive towards atomistic individualization (you are sick because of your brain chemistry). Second, it provides an enormously lucrative market in which multinational pharmaceutical companies can peddle their pharmaceuticals (we can cure you with our SSRIs). It goes without saying that all mental illnesses are neurologically instantiated, but this says nothing about their causation. If it is true, for instance, that depression is constituted by low serotonin levels, what still needs to be explained is why particular individuals have low levels of serotonin. This requires a social and political explanation; and the task of repoliticizing mental illness is an urgent one if the left wants to challenge capitalist realism.

Some have estimated that the pharmaceutical industry overall spends about twice as much on marketing and promotion as it does on research and development.

No,” said a third student. “Novartis is a public company. It’s not the boss or the board who decides. It’s the shareholders. If the board changes its priorities the shareholders will just elect a new board.” “That’s right,” I said. “It’s the shareholders who want this company to spend their money on researching rich people’s illnesses. That’s how they get a good return on their shares.” So there’s nothing wrong with the employees, the boss, or the board, then. “Now, the question is”—I looked at the student who had first suggested the face punching—“who owns the shares in these big pharmaceutical companies?” “Well, it’s the rich.” He shrugged. “No. It’s actually interesting because pharmaceutical shares are very stable. When the stock market goes up and down, or oil prices go up and down, pharma shares keep giving a pretty steady return. Many other kinds of companies’ shares follow the economy—they do better or worse as people go on spending sprees or cut back—but the cancer patients always need treatment. So who owns the shares in these stable companies?” My young audience looked back at me, their faces like one big question mark. “It’s retirement funds.” Silence. “So maybe I don’t have to do any punching, because I will not meet the shareholders. But you will. This weekend, go visit your grandma and punch her in the face. If you feel you need someone to blame and punish, it’s the seniors and their greedy need for stable stocks.

Can these foods [low-fat, vitamin-enriched, etc] even be called "healthy"? Perhaps we should think about it this way: If you cut a batch of pharmaceutical-grade cocaine with chai, you could say with some degree of honesty that it is "healthier," "less addictive," and "now with chai!" But would you say it's "good for you"?

But Arthur Sackler is important to this story because he founded modern pharmaceutical advertising and, in the words of John Kallir, showed the industry “that amazing things can be achieved with direct selling and intensive direct advertising.” Years later, Purdue would put those strategies to use marketing its new opiate painkiller OxyContin.

No single individual did more to shape the character of medical advertising than the multi-talented Dr. Arthur Sackler.” It was Arthur, the citation continued, who brought “the full power of advertising and promotion to pharmaceutical marketing.

At this time we should take a brife moment to mention quacks: alternative therapists who sell vitamins and homeopathy sugar pills [the latter of which, by definition, contain no active ingredients], which perform no better than placebo in fair tests, and who use even cruder marketing tricks than the ones described in this book. In these people profit at all from the justified anger that people feel towards the pharmaceutical industry, then it comes at the expense of genuinely constructive activity. Selling ineffective sugar pills is not a meaningful policy response to the regulatory failure we have seen in this book

What makes our contemporary neurobiological concepts different is the extent to which they have been promoted by pharmaceutical marketers. You are not shy; you have social anxiety disorder. You are not absentminded, dreamy, or fidgety; you have ADHD. You are not moody; you are bipolar. Each diagnosis comes with a prescription. Your need for medication becomes part of your identity.

When a pharmaceutical company releases a new drug, they have a big launch meeting, which can seem like some unholy combination of a bachelor party, a marketing convention, and a revival meeting.

Here we will see that pharmaceutical companies spend tens of billions of pounds every year trying to change the treatment decisions of doctors: in fact, they spend twice as much on marketing and advertising as they do on the research and development of new drugs. Since we all want doctors to prescribe medicine based on evidence, and evidence is universal, there is only one possible reason for such huge spends: to distort evidence-based practice.

the Times says there's a heroin epidemic, Malone thinks, which is only an epidemic of course because now white people are dying. Whites started to get opium-based pills from their physicians: oxycodone, vicodin... But, it was expensive and doctors were reluctant to prescribe too much for exactly the fear of addiction. So the white folks went to the open market and the pills became a street drug. It was all very nice and civilized until the Sinoloa cartel down in Mexico made a corporate decision that it could undersell the big American pharmaceutical companies by raising production of its heroin thereby reducing price. As an incentive, they also increased its potency. The addicted white Americans found that Mexican ... heroin was cheaper and stronger than the pills, and started shooting it into their veins and overdosing. Malone literally saw it happening. He and his team busted more bridge-and-tunnel junkies, suburban housewives and upper Eastside madonnas than they could count....

Thus, if any FDA-approved drug like hydroxychloroquine (or ivermectin) proved effective against COVID, pharmaceutical companies would no longer be legally allowed to fast-track their billion-dollar vaccines to market under Emergency Use Authorization.

Key fact: in 2003 pharmaceutical companies spent more on marketing and sales than they did on research and development. When it comes time to invest, it’s pretty clear that spreading the ideas behind the medicine is more important than inventing the medicine itself.

It was Arthur Sackler who would be credited not just with this campaign but with revolutionizing the whole field of medical advertising. In the words of one of his longtime employees at McAdams, when it came to the marketing of pharmaceuticals, “Arthur invented the wheel.

There are lots of planned economies-the United States is a planned economy, for example. I mean, we talk ourselves as a "free market", but that's baloney. The only parts of the U.S. economy that are internationally competitive are the planned parts, the state-subsidized parts--like capital-intensive agriculture (which has a state-guaranteed market as a cushion in case there are excesses); or high-technology industry (which is dependent on the Pentagon system); or pharmaceuticals (which is massively subsidized by publically funded research). Those are the parts of the U.S. economy that are functioning well.

Csikszentmihalyi teamed up with two other leading psychologists—Howard Gardner at Harvard, and William Damon at Stanford—to study these changes, and to see why some professions seemed healthy while others were growing sick. Picking the fields of genetics and journalism as case studies, they conducted dozens of interviews with people in each field. Their conclusion32 is as profound as it is simple: It’s a matter of alignment. When doing good (doing high-quality work that produces something of use to others) matches up with doing well (achieving wealth and professional advancement), a field is healthy. Genetics, for example, is a healthy field because all parties involved respect and reward the very best science. Even though pharmaceutical companies and market forces were beginning to inject vast amounts of money into university research labs in the 1990s, the scientists whom Csikszentmihalyi, Gardner, and Damon interviewed did not believe they were being asked to lower their standards, cheat, lie, or sell their souls. Geneticists believed that their field was in a golden age in which excellent work brought great benefits to the general public, the pharmaceutical companies, the universities, and the scientists themselves.

After the first study came out in 2007, I started experimenting with methylene blue, with mixed results. The biggest concern is getting good-quality methylene blue, given that most of what’s on the market is chemical grade or used to keep fish tanks clean. I found pharmaceutical-grade methylene blue and kept the dose low. The safe range is 1–4 mg per kg of body weight.18

Over the last fifty years at NIH, Dr. Fauci has played a leading role in Big Pharma’s engineered demolition of American health and democracy, working hand in glove with pharmaceutical companies to overcome federal regulatory obstacles and transform the NIH and NIAID into a single-minded vehicle for development, promotion, and marketing of patented pharmaceutical products, including vaccines and vaccine-like products.

In 1955 a drug company named Carter-Wallace released the anti-anxiety drug Miltown, reframing anxiety as the natural product of a society that was both dog-eat-dog and relentlessly social. Miltown was marketed to men and immediately became the fastest-selling pharmaceutical in American history, according to the social historian Andrea Tone. By 1956 one of every twenty Americans had tried it; by 1960 a third of all prescriptions from U.S. doctors were for Miltown or a similar drug called Equanil.

And if the history of pharmaceutical consumption is any indication, many buckled under such pressures. In 1955 a drug company named Carter-Wallace released the anti-anxiety drug Miltown, reframing anxiety as the natural product of a society that was both dog-eat-dog and relentlessly social. Miltown was marketed to men and immediately became the fastest-selling pharmaceutical in American history, according to the social historian Andrea Tone. By 1956 one of every twenty Americans had tried it; by 1960 a third of all prescriptions from U.S. doctors were for Miltown or a similar drug called Equanil.

Some have estimated that the pharmaceutical industry overall spends about twice as much on marketing and promotion as it does on research and development. Regardless of how those two figures compare to each other, the fact that they are in the same ballpark gives one pause, and this is worth mulling over in various contexts. For example, when a drug company refuses to let a developing country have affordable access to a new AIDS drug it’s because – the company says – it needs the money from sales to fund research and development on other new AIDS drugs for the future. If R&D is a fraction of the company’s outgoings, and it spends a similar amount on promotion, then this moral and practical argument doesn’t hold water quite so well.

All the recent marketing successes have been PR successes, not advertising successes. To name a few: Starbucks, The Body Shop, Amazon.com, Yahoo!, eBay, Palm, Google, Linus, PlayStation, Harry Potter, Botox, Red Bull, Microsoft, Intel, and BlackBerry. A closer look at the history of most major brands shows this to be true. As a matter of fact, an astonishing number of well-known brands have been built with virtually no advertising at all. Anita Roddick built The Body Shop into a worldwide brand without any advertising. Instead she traveled the world looking for ingredients for her natural cosmetics, a quest that resulted in endless publicity. Until recently Starbucks didn’t spend a hill of beans on advertising either. In its first ten years, the company spent less that $10 million (total) on advertising in the United States, a trivial amount for a brand that delivers annual sales of $1.3 billion today. Wal-Mart became the world’s largest retailer, ringing up sales approaching $200 billion, with little advertising. Sam’s Club, a Wal-Mart sibling, averages $56 million per store with almost no advertising. In the pharmaceutical field, Viagra, Prozac, and Vioxx became worldwide brands with almost no advertising. In the toy field, Beanie Babies, Tickle Me Elmo, and Pokémon became highly successful brands with almost no advertising. In the high-technology field, Oracle, Cisco, and SAP became multibillion-dollar companies (and multibillion-dollar brands) with almost no advertising.

This is an existential threat to the social and economic order, which is why countries wage a stubborn, bloody and hopeless war on biochemical crime. The state hopes to regulate the biochemical pursuit of happiness, separating ‘bad’ manipulations from ‘good’ ones. The principle is clear: biochemical manipulations that strengthen political stability, social order and economic growth are allowed and even encouraged (e.g., those that calm hyperactive kids in school, or drive anxious soldiers forward into battle). Manipulations that threaten stability and growth are banned. But each year new drugs are born in the research labs of universities, pharmaceutical companies and criminal organisations, and the needs of the state and the market also keep changing.

In 1955 a drug company named Carter-Wallace released the anti-anxiety drug Miltown, reframing anxiety as the natural product of a society that was both dog-eat-dog and relentlessly social. Miltown was marketed to men and immediately became the fastest-selling pharmaceutical in American history, according to the social historian Andrea Tone. By 1956 one of every twenty Americans had tried it; by 1960 a third of all prescriptions from U.S. doctors were for Miltown or a similar drug called Equanil. “ANXIETY AND TENSION ARE THE COMMONPLACE OF THE AGE,” read the Equanil ad. The 1960s tranquilizer Serentil followed with an ad campaign even more direct in its appeal to improve social performance. “FOR THE ANXIETY THAT COMES FROM NOT FITTING IN,” it empathized.

Some have estimated that the pharmaceutical industry overall spends about twice as much on marketing and promotion as it does on research and development. Regardless of how those two figures compare to each other, the fact that they are in the same ballpark gives one pause, and this is worth mulling over in various contexts. For example, when a drug company refuses to let a developing country have affordable access to a new AIDS drug it’s because – the company says – it needs the money from sales to fund research and development on other new AIDS drugs for the future. If R&D is a fraction of the company’s outgoings, and it spends a similar amount on promotion, then this moral and practical argument doesn’t hold water quite so well. The scale of this spend is fascinating in itself, when you put it in the context of what we all expect from evidence-based medicine, which is that people will simply use the best treatment for the patient. Because when you pull away from the industry’s carefully fostered belief that this marketing activity is all completely normal, and stop thinking of drugs as being a consumer product like clothes or cosmetics, you suddenly realise that medicines marketing only exists for one reason. In medicine, brand identities are irrelevant, and there’s a factual, objective answer to whether one drug is the most likely to improve a patient’s pain, suffering and longevity. Marketing, therefore, one might argue, exists for no reason other than to pervert evidence-based decision-making in medicine.

The state hopes to regulate the biochemical pursuit of happiness, separating ‘bad’ manipulations from ‘good’ ones. The principle is clear: biochemical manipulations that strengthen political stability, social order and economic growth are allowed and even encouraged (e.g. those that calm hyperactive kids in school, or drive anxious soldiers forward into battle). Manipulations that threaten stability and growth are banned. But each year new drugs are born in the research labs of universities, pharmaceutical companies and criminal organisations, and the needs of the state and the market also keep changing. As the biochemical pursuit of happiness accelerates, so it will reshape politics, society and economics, and it will become ever harder to bring it under control.

He generally traveled to Europe four or five times a year. The pharmaceutical empire he ran had research centers in Germany, Switzerland, and France, and huge laboratories and factories in England. It was always interesting coming over here, exchanging ideas with their research teams, and exploring new avenues of marketing, which was his real forte. But this time it was far more than that, far more than just a research trip, or the unveiling of a new product. He was here for the birth of “his baby.” Vicotec. His life’s dream. Vicotec was going to change the lives and the outlook of all people with cancer. It was going to dramatically alter maintenance programs, and the very nature of chemotherapy the world over. It would be Peter’s one major contribution to the human race. For the past four years, other than his family, it was what he had lived for. And undeniably, it was going to make Wilson-Donovan millions. More than that, obviously, their studies had already projected earnings in the first five years to well over a

Here is another example that demonstrates the tightly linked interests that both cause and treat cancer. In 1978, Imperial Chemical Industries (ICI), one of the largest companies in the world, specializing in agrochemicals and pharmaceuticals, developed the cancer drug tamoxifen. In 1985, along with the American Cancer Society, ICI founded the National Breast Cancer Awareness Month with the aim of promoting mammography as the most effective tool against breast cancer. In 1990 Imperial Chemical Industries was accused of dumping DDT and PCBs, known carcinogens, into the Long Beach and Los Angeles harbors. Zeneca, producer of tamoxifen, demerged from ICI in 1993, and later merged with Astra AB in 1999 to form AstraZeneca. Astra AB had developed the herbicide acetochlor, classified by the EPA as a probable carcinogen. In 1997 Zeneca purchased Salick Health Care, a chain of for-profit outpatient cancer clinics. Subsequently AstraZeneca launched a major publicity campaign encouraging women to assess their risk factors for breast cancer, downplaying the dangers of tamoxifen in order to create a market for its prophylactic, or chemopreventative, use and, more recently, for the breast cancer drug Arimidex (anastrozole), approved in 2002 and used as an alternative to tamoxifen (Arimidex went off patent in 2010).

Professor Joseph Stiglitz, former Chief Economist of the World Bank, and former Chairman of President Clinton's Council of Economic Advisers, goes public over the World Bank’s, “Four Step Strategy,” which is designed to enslave nations to the bankers. I summarise this below, 1. Privatisation. This is actually where national leaders are offered 10% commissions to their secret Swiss bank accounts in exchange for them trimming a few billion dollars off the sale price of national assets. Bribery and corruption, pure and simple. 2. Capital Market Liberalization. This is the repealing any laws that taxes money going over its borders. Stiglitz calls this the, “hot money,” cycle. Initially cash comes in from abroad to speculate in real estate and currency, then when the economy in that country starts to look promising, this outside wealth is pulled straight out again, causing the economy to collapse. The nation then requires International Monetary Fund (IMF) help and the IMF provides it under the pretext that they raise interest rates anywhere from 30% to 80%. This happened in Indonesia and Brazil, also in other Asian and Latin American nations. These higher interest rates consequently impoverish a country, demolishing property values, savaging industrial production and draining national treasuries. 3. Market Based Pricing. This is where the prices of food, water and domestic gas are raised which predictably leads to social unrest in the respective nation, now more commonly referred to as, “IMF Riots.” These riots cause the flight of capital and government bankruptcies. This benefits the foreign corporations as the nations remaining assets can be purchased at rock bottom prices. 4. Free Trade. This is where international corporations burst into Asia, Latin America and Africa, whilst at the same time Europe and America barricade their own markets against third world agriculture. They also impose extortionate tariffs which these countries have to pay for branded pharmaceuticals, causing soaring rates in death and disease.

Clip This Article on Location 1397 | Added on Monday, September 1, 2014 4:10:39 PM REVIEW & OUTLOOK An $8.3 Billion Rebuke to the FDA Roche buys a drug approved in Europe but not in America. 359 words Amid this summer's M&A fever, Roche's agreement Monday to buy the San Francisco biotech InterMune deserves special notice. The tie-up is an $8.3 billion guided missile into the fortified bunker that is the Food and Drug Administration. InterMune has never turned a profit in 16 years of existence and other than its clinical expertise the company holds a single asset: an idea for treating a lethal lung disorder called idiopathic pulmonary fibrosis with no known cause, cure or approved therapy—at least in the U.S. An InterMune drug called pirfenidone that slows the progression of irreversible lung scarring is on the market in Europe, Japan, Canada and even China. Bloomberg News But the FDA refused to approve pirfenidone in 2010, despite the 40,000 Americans who are killed annually by lung fibrosis and a positive recommendation from its outside scientific advisory committee. The agency brass claimed the evidence was statistically unsatisfactory, when one clinical trial was inconclusive but another showed strong benefits such as improved lung function. The results of the third trial the FDA ordered were reported earlier this year and confirmed that pirfenidone is even more of a treatment advance than it seemed in 2010, and may prolong life. The agency is expected, finally, to approve the medicine in November. Roche is paying a 38% premium over Friday's closing share price, and 63% over trading before the news of InterMune's corporate suitors broke a few weeks ago. The deal is a big vote of confidence in pirfenidone, not least because a rival lung fibrosis drug is awaiting U.S. approval. Then again, maybe that drug's maker, the German pharmaceutical consortium Boehringer Ingelheim, will have the same FDA experience as InterMune. The Roche deal is a tacit reprimand to the FDA's unscientific and uncompassionate—and wrong—2010 defenestration. Amid medical ambiguity about effectiveness, the humane option is to allow a drug to come to patients and follow on with more research, in particular for a drug with few side effects. Pulmonary fibrosis is a protracted death sentence of three to five years. The FDA denied tens of thousands of dying people better and possibly longer lives in the time they had left. ==========

Zeneca Pharmaceuticals, the ICI spin-off that now exclusively funds and controls Breast Cancer Awareness Month, earns more than $300 million a year from the sale of a carcinogenic herbicide (acetochlor) while simultaneously marketing Tamoxifen, which has now become the world's bestselling cancer therapy drug.

Healthcare marketing is a powerful tool that is about more than profits: It can deliver the information that will add years to people’s lives. To gain market share and grow the brand is extremely important to any business, of course. But any business is all about people. As an industry, we need to grasp the opportunity to serve patients more intimately and immediately.

We live in an age when relevant information can be readily found. The world is awash in more information than ever before. The ability to deliver targeted quality information, education, and services when they are needed most represents a massive opportunity for our entire healthcare ecosystem.

We are in a noble and inspiring business. The essence of our industry is to help people get better, manage their conditions, and extend their lives. What an awesome reason to get up every day and go to work!

It will involve figuring out where in the country a product will work better, in terms of both efficacy and revenue. It will involve more than sending out an army of sales reps who often can’t get in the door anymore. It will take advantage of new digital promotion tools and targeting. It will harness big data for a far better understanding of competitive advantages, ideal patient populations, and how medicines can be personalized to the individual.

What they need, above all, is to sincerely connect with a source of useful and relevant information. These moments represent incredible opportunities for the pharmaceutical and healthcare industry to help and be of service.

When the pharmaceutical marketers of the future communicate with patients, those communications will need to be personal and meaningful, as well as useful and valuable if we expect them to take actions that yield results.

Anyone can market a product that is significantly better than the competition’s. It is another story if the product is only slightly better. To win in today’s world requires a better approach.

Superior pharmaceutical marketing of the future will involve understanding the nuances of why certain patient populations excel with a product and why others struggle. This will come about through an understanding of real-world data, the only data that really matters. As

In fact, only two studies are required for FDA licensure of most pharmaceuticals, essentially leaving the population to participate in a post-marketing experiment in which adverse effects—causalities—are monitored passively. It’s a fabrication of science to think these drugs have a place in medicine, what is meant to be the art of healing. It

Politics, like insurance, security, pharmaceutical and religious institutions all work the same. They sell the idea of a threat along with the antidote. Marketing 101.

The notion that hormonal contraception could keep a newly formed oocyte from adhering to the uterine wall had no scientific basis. The pharmaceutical company that had first marketed the pill in the fifties had made the claim—without any scientific data—because they thought it would help sell the product. Now a growing number of anti-abortion activists, including some doctors, believed it to be factual. Marketing was the glue that held myths together.

army of people paid to “gaslight” the public into thinking they are protected. Chapter 23, page 132. Trick #17 for Farming Humans is using stock markets to launder taxpayer backed, Fed created money to those who control the Fed. Chapter 25, page 136. Trick #18 for Farming Humans is the use of fake information to ensure that society never knows what is true and what is false. Elections, wars, headlines etc. Chapter 26, page 141. Trick #19 for Farming Humans is stimulation and distraction. This emotional hacking of humans is Trick #19 for Farming Humans. See Social Engineering: The Art of Human Hacking Book by Christopher J. Hadnagy Trick #20 for Farming Humans is the elimination of the Fairness Doctrine and 83 media regulations, including requirement for “honest, equitable and balanced”. Chapter 28, page 153. Trick #21 for Farming Humans is governments as handmaidens to corporations, not people. Chapter 29, page 157. Trick #22 for Farming Humans is in the invisible connections between government, professionals and corporations. Chapter 31, page 162. Laws, lobby groups, lawyers. Trick #23 for Farming Humans is a militarized police used to serve and protect power instead of people. Chapter 32, page 170. World Trade Organization, Occupy Wall Street, Black Lives Matter, etc. Trick #24 for Farming Humans is virtually zero enforcement of crime above a certain level of money or power. Invisible friends and powerful people cannot be prosecuted. Chapter 33, page 175. Trick #25 for Farming Humans is cooking the financial books. Chapter 34, page 180. Valeant Pharmaceutical, IFRS vs GAP accounting standards, audit numbers rigged. Trick #26 for Farming Humans is printing infinite money to exchange for finite goods…”let me handle that for you.” Chapter 35, page 184. Trick #27 for Farming Humans is public servants spying on the public, and not on the public servants. Chapter 36, page 188.

The dysfunctional state of the American political system is the best reason to be pessimistic about our country’s future. Our scientific and technological prowess is the best reason to be optimistic. We are an inventive people. The United States produces ridiculous numbers of patents,114 has many of the world’s best universities and research institutions, and our companies lead the market in fields ranging from pharmaceuticals to information technology. If I had a choice between a tournament of ideas and a political cage match, I know which fight I’d rather be engaging in—especially if I thought I had the right forecast.

The impact of vaccination has been estimated during the “vaccines for children era” (1994–2013) at the total number of more than 322 million prevented cases of infectious diseases, 21 million avoided hospitalizations, and 731,700 avoided deaths in the United States.

Define their industry similarly and focus on being the best within it Look at their industries through the lens of generally accepted strategic groups (such as luxury automobiles, economy cars, and family vehicles), and strive to stand out in the strategic group they play in Focus on the same buyer group, be it the purchaser (as in the office equipment industry), the user (as in the clothing industry), or the influencer (as in the pharmaceutical industry) Define the scope of the products and services offered by their industry similarly Accept their industry’s functional or emotional orientation Focus on the same point in time—and often on current competitive threats—in formulating strategy

Like all best supporting actors, the state may also step centre stage, taking entrepreneurial risks where the market and commons can’t or won’t reach. The extraordinary success of tech companies such as Apple is sometimes held up as evidence of the market’s dynamism. But Mariana Mazzucato, an expert in the economics of government-led innovation, points out that the basic research behind every innovation that makes a smart phone ‘smart’—GPS, microchips, touchscreens and the Internet itself—was funded by the US government. The state, not the market, turns out to have been the innovating, risk-taking partner, not ‘crowding out’ but ‘dynamising in’ private enterprise—and this trend holds across other high-tech industries too, such as pharmaceuticals and biotech.42 In the words of Ha-Joon Chang, ‘If we remain blinded by the free market ideology that tells us only winner-picking by the private sector can succeed, we will end up ignoring a huge range of possibilities for economic development through public leadership or public-private joint efforts.

Our pursuit of instant gratifications and instant progress has been leading us down the path of mental deterioration and we seem to be completely unaware of it. And if this continues, then soon serenity will become the most expensive commodity in the market - which will be sold to everyone by the pharmaceutical industry in the form of pills and treatments.

Men! God only put them on earth so pharmaceutical companies would have a market for Prozac and Valium.

nevertheless pleaded guilty to criminal charges and paid a $3 billion fine for promoting its antidepressants for unapproved uses and failing to report safety data about a top diabetes drug. It was the largest settlement recorded involving a pharmaceutical company. The agreement also included civil penalties for improper marketing of a half-dozen

Commercial Operations, Global Pricing, Reimbursement and Market Access, Contract Strategy, Operations and Compliance for large pharmaceutical companies.

pass across virtually all areas of public policy. As Frederick Winslow Taylor’s principles of scientific management gained traction, progressives began to see expertise and a professional civil service as a way to insulate policy making from corruption. During Roosevelt’s time, the Pure Food and Drug Act and the Meat Inspection Act (both passed in 1906) created federal regulation of food and pharmaceuticals. Throughout the twentieth century, federal regulation would become the dominant model in a variety of areas. Aviation, occupational safety, consumer products, clean water, clean air, hazardous materials—all are areas in which the national government regulates markets to protect the public from the misuse of corporate power and to advance the public interest. Roosevelt’s incorporation law simply applied

About a quarter of the money taken by pharmaceutical companies for the drugs they sell is turned around into promotional activity which has, as we will see, a provable impact on doctors' prescribing. So we pay for products, with a huge uplift in price to cover their marketing budgets, and that money is then spent on distorting evidence-based practice, which in turn makes our decisions unnecessarily expensive, and less effective.

pharmaceutical companies spend tens of billions of pounds every year trying to change the treatment decisions of doctors: in fact, they spend twice as much on marketing and advertising as they do on the research and development of new drugs. Since we all want doctors to prescribe medicine based on evidence, and evidence is universal, there is only one possible reason for such huge spends: to distort evidence-based practice.

Well, it depends which planned economies you mean. There are lots of planned economies―the United States is a planned economy, for example. I mean, we talk about ourselves as a "free market," but that's baloney. The only parts of the U.S. economy that are internationally competitive are the planned parts, the state-subsidized parts―like capital-intensive agriculture (which has a state-guaranteed market as a cushion in case there are excesses); or high-technology industry (which is dependent on the Pentagon system); or pharmaceuticals (which is massively subsidized by publicly-funded research). Those are the parts of the U.S. economy that are functioning well. And if you go to the East Asian countries that are supposed to be the big economic successes―you know, what everybody talks about as a triumph of free-market democracy—they don't even have the most remote relation to free-market democracy: formally speaking they're fascist, they're state-organized economies run in cooperation with big conglomerates. That's precisely fascism, it's not the free market. Now, that kind of planned economy "works," in a way―it produces at least. Other kinds of command economies don't work, or work differently: for example, the Eastern European planned economies in the Soviet era were highly centralized, over-bureaucratized, and they worked very inefficiently, although they did provide a kind of minimal safety-net for people. But all of these systems have been very anti-democratic―like, in the Soviet Union, there were virtually no peasants or workers involved in any decision-making process.

From the outset, hydroxychloroquine (HCQ) and other therapeutics posed an existential threat to Dr. Fauci and Bill Gates’ $48 billion COVID vaccine project, and particularly to their vanity drug remdesivir, in which Gates has a large stake.1 Under federal law, new vaccines and medicines cannot quality for Emergency Use Authorization (EUA) if any existing FDA-approved drug proves effective against the same malady: For FDA to issue an EUA (emergency use authorization), there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition. . . .2 Thus, if any FDA-approved drug like hydroxychloroquine (or ivermectin) proved effective against COVID, pharmaceutical companies would no longer be legally allowed to fast-track their billion-dollar vaccines to market under Emergency Use Authorization. Instead, vaccines would have to endure the years-long delays that have always accompanied methodical safety and efficacy testing, and that would mean less profits, more uncertainty, longer runways to market, and a disappointing end to the lucrative COVID-19 vaccine gold rush. Dr. Fauci has invested $6 billion in taxpayer lucre in the Moderna vaccine alone.3 His agency is co-owner4 of the patent and stands to collect a fortune in royalties. At least four of Fauci’s hand-picked deputies are in line to collect royalties of $150,000/year based on Moderna’s success, and that’s on top of the salaries already paid by the American public.5,6

The headline of a comprehensive exposé in The Guardian expressed the global shock among the scientific community at the rank corruption by scientific publishing’s most formidable pillars: “The Lancet has made one of the biggest retractions in modern history. How could this happen?”94 The Guardian writers openly accused The Lancet of promoting fraud: “The sheer number and magnitude of the things that went wrong or missing are too enormous to attribute to mere incompetence.” The Guardian commented, “What’s incredible is that the editors of these esteemed journals still have a job—that is how utterly incredible the supposed data underlying the studies was.” The capacity of their Pharma overlords to strong-arm the world’s top two medical journals, the NEJM and The Lancet, into condoning deadly research95,96 and to simultaneously publish blatantly fraudulent articles in the middle of a pandemic, attests to the cartel’s breathtaking power and ruthlessness. It is no longer controversial to acknowledge that drug makers rigorously control medical publishing and that The Lancet, NEJM, and JAMA are utterly corrupted instruments of Pharma. The Lancet editor, Richard Horton, confirms, “Journals have devolved into information laundering operations for the pharmaceutical industry.”97 Dr. Marcia Angell, who served as an NEJM editor for 20 years, says journals are “primarily a marketing machine.”98 Pharma, she says, has co-opted “every institution that might stand in its way.”99,100 Cracking Down on HCQ to Keep Case Fatalities High Referring to the Lancet Surgisphere study during a May 27 CNN interview, Dr. Fauci stated on CNN about hydroxychloroquine,

As I make clear throughout the book, OxyContin was hardly the only opioid to be fraudulently marketed or widely abused, and my choice to focus on Purdue is in no way a suggestion that other pharmaceutical companies do not deserve a great deal of blame for the crisis. The same could be said for the FDA, the doctors who wrote prescriptions, the wholesalers that distributed the opioids, and the pharmacies that filled the prescriptions. There’s plenty of blame to go around. I do share the view, however, of many doctors, public officials, prosecutors, and scholars that Purdue played a special role, as a pioneer. All

Under federal law, new vaccines and medicines cannot quality for Emergency Use Authorization (EUA) if any existing FDA-approved drug proves effective against the same malady: For FDA to issue an EUA (emergency use authorization), there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition. . . .2 Thus, if any FDA-approved drug like hydroxychloroquine (or ivermectin) proved effective against COVID, pharmaceutical companies would no longer be legally allowed to fast-track their billion-dollar vaccines to market under Emergency Use Authorization. Instead, vaccines would have to endure the years-long delays that have always accompanied methodical safety and efficacy testing, and that would mean less profits, more uncertainty, longer runways to market, and a disappointing end to the lucrative COVID-19 vaccine gold rush. Dr. Fauci has invested $6 billion in taxpayer lucre in the Moderna vaccine alone.3 His agency is co-owner4 of the patent and stands to collect a fortune in royalties. At least four of Fauci’s hand-picked deputies are in line to collect royalties of $150,000/year based on Moderna’s success, and that’s on top of the salaries already paid by the American public.5

The over-use of antibiotics is also causing more bacteria to become resistant. Today, 70 percent of microbes held responsible for lung illnesses no longer respond to medications.180 The increase in resistance prompts the pharmaceutical sector to conduct more intensive research for new antibiotics. But the discovery of such molecules is a long, difficult and costly process (about $600 million per molecule).181 For many years, no important new antibiotic has come onto the market. At the same time, increasingly stronger preparations are being introduced, which only leads to the bacteria becoming even more resistant and excreting even more toxins.

In the Adaptive Markets framework, complexity means we don't have a good narrative for the system. The solution is obvious: we need to get smarter. Complexity can sometimes be reduced by developing a deeper understanding of the underlying structure of the system. For example, now that we understand the potential for liquidity spirals in statarb portfolios, thanks to August 2007, we can better prepare for them. But the Adaptive Markets framework points to a second problem with complexity, which is the potential divisiveness of special knowledge and the potential for conflict. If the financial system becomes so complex that only a small number of elites truly understand its function and proper maintenance, this knowledge divides the population into those who know and those who don't. Of course, this situation arises with any piece of unique information - I know how to make scallion pancakes in a particular way so they're crispy on the outside but soft and chewy on the inside, and you probably don't. But that piece of knowledge is hardly worth keeping a secret, and the fact that you don't have that knowledge isn't going to get you too upset. But suppose I know how to cure diabetes and you don't. Or I know how to prevent cancer by avoiding certain common foods and you don't. Or I know how to price mortgage-backed securities and credit default swaps and you don't. In these cases, the knowledge I possess confers a certain power and status to me. Complexity creates the need for better narratives and those who have those narratives will become the high priests of complex systems, the gatekeepers of critical, life-altering knowledge. And the difficulty in joining the priesthood - earning an MD/Ph.D. in molecular biology and having twenty year of work experience at biotech and pharmaceutical companies, in the case of curing diabetes - coupled with the societal values of the special knowledge will determine the divisiveness of this elitism.

Pharmaceutical Product Exporters in Ahmedabad India’s Leading Exporters of Quality Pharmaceutical Formulations in India. We offer Pharmaceutical Drug Formulation and Pharmaceutical Marketers. Research Pvt. Ltd. is top manufacturing the anti-infective Tablets. We have a wide range of pharmaceutical product exporters in Ahmedabad India. ERPL is one of the fastest growing pharmaceutical manufacturing company in India. Spread over 1,47,500 sq. ft. acres, this modernized manufacturing plant with ultra-modern facility is set up in North Indian State of Uttarakhand. The facilities are approved by cGMP, WHO-GMP, GLP, ISO 9001:2000 and other global regulatory bodies. ERPL has carved out a distinct place of its own in manufacturing of best quality pharmaceutical products. Our success is the mirror of the hard work and team spirit put up the excellence of the professionalism by our dedicated Directors to excel and concurred new horizons with the motive of “Commit to Quality and Customer Satisfaction” Manufacturing Facility Installed with latest technology, automated manufacturing and packing operation and best practices, ensuring the highest quality of healthcare. • Commitment and zero compromise on quality • Follow up WHO-GMP, CGMP and GLP • Instrument Lab • Primary Area • Analytical Lab • Production process • Quality Management system • Process and products design, Evolution & Validation of process.

PCD & Franchise Company, International Standard Quality Products in Ahmedabad Gujarat India. Desta Life Sciences is the top PCD Pharma Franchise company in India. We are procured from faithful vendors to ensure its International Standard Quality Products. We're at Desta Science for Health Life providing the best PCD Franchise for business. This is the best Business Opportunity in India. We have 200+ Products, 4 Divisions and 13 Innovative Products. Desta Lifesciences, Started in 2011. The company's philosophy has been rooted in Quality and care and it is this ideology that has kept us alive through ups and downs. The company's greatest asset has always been its employees and it is in them we place our trust to shoulder the company's corporate responsibility and to uphold the company's ideals and values. A healthy blend of World-Class Quality, Disease prevalence-dependent, wide variety of products, stress on preventive Lifestyle products, a positive upbeat mood of one & all in the company and a feeling of oneness, is the recipe that Desta Lifesciences presents humbly to humanity. The "For the people, By the People" dictum is followed by the management in the company, thus making it surge forward with the force of the common goal to accomplish our Mission. We aim to serve mankind globally through our affordable and international standard quality products, encompassing the environmental synergy in the process. As we enter into the technological age of pharmaceuticals, we promise to adapt to more advanced technologies while simultaneously focusing on delivery of care. The future holds great promise as we gradually hope to venture into Exports and R&D to establish ourselves in the global market.

Esmero is a leading Pharmaceutical Manufacturing Company in India. We are providing manufacture the best quality pharmaceutical products in India. India’s Leading Exporters of Quality Pharmaceutical Formulations in India. We offer Pharmaceutical Drug Formulation and Pharmaceutical Marketers. ERPL is one of the fastest growing Pharmaceutical Manufacturing Company in India. Spread over 1,47,500 sq. ft. acres, this modernized manufacturing plant with ultra-modern facility is set up in North Indian State of Uttarakhand.

Narrowness and pragmatism are characteristic of the dominant ways of thought under capitalism, where the individualism of economic man is a model for the autonomy and isolation of all phenomena, and where a knowledge industry turns scientific ideas into marketable commodities—precisely the magic bullets that the pharmaceutical industry sells people.

MITI, far from being a uniquely brilliant leader of government/industrial partnership, has been wrong so often that the Japanese themselves will concede that much of their growth derives from industry's rejection of MITI’s guidance. MITI, incredibly, opposed the development of the very areas where Japan has been successful: cars, electronics and cameras. MITI has, moreover, poured vast funds into desperately wasteful projects. Thanks to MITI, Japan has a huge overcapacity in steel - no less than three times the national requirement. This, probably the most expensive mistake Japan ever made in peacetime, was a mistake of genius, because Japan has no natural resources: it has to import everything; the iron ore, the coal, the gas, the limestone and the oil to make its unwanted steel. Undaunted, MITI then invested in giant, loss-making (£400 million losses by 1992) 5th generation supercomputers at the precise moment that the market opened for the small personal computer; and MITI' s attempts at dominating the world's pharmaceutical and telecommunications industries have each failed. Nor is this just anecdote. In a meticulous study of MITI’s interventions into the Japanese economy between 1955 and 1990, Richard Beason of Alberta University and David Weinterin of Harvard showed that, across the 13 major sectors of the economy, surveying hundreds of different companies, Japan's bureaucrats almost invariably picked and supported the losers.

At present, psychiatry is ruled by the biomedical model, which attributes all disturbed mental and emotional function to imbalances in brain chemistry, treatable with drugs. If this were the whole story, psychiatric drugs would be much more effective than they are. Pharmaceutical companies exaggerate their benefits and downplay their risks in marketing them to both doctors and the public.

Thus, important parts of physics and chemistry have been pressed into the service of war and destruction; much mathematical and statistical ingenuity has been turned into an auxiliary of monopolistic market control and profit maximization; psychology has become a prostitute of 'motivation research' and personnel management; biology is made into a handmaiden of pharmaceutical rackets; and art, language, color, and sound have been degraded into instrumentalities of advertising.

But as it happened, a team of chemists in Germany had recently managed to refine morphine into a new drug, heroin, which the German pharmaceutical company Bayer began to mass market as a wonder drug—a safer alternative to morphine. Heroin was created by the same research team that invented aspirin.

Once the product gets to market, the pharmaceutical company pays royalties—a form of legalized kickbacks—through an informal scheme that allows Pharma to funnel its profits from drug sales to NIAID and to the NIAID officials who worked on the product. Under a secretive, unpromulgated HHS policy, Dr. Fauci and his NIAID underlings may personally pocket up to $150,000 annually from drugs they helped develop at taxpayers’ expense

Encouraged by relaxed licensing requirements, pharmaceutical companies have flooded the market with unnecessary, poorly tested, and ineffective vaccines since the late 1970s. The focus is on creating wealth and jobs rather than quality products backed by sound medical and scientific evidence. In the United States alone, there are currently eighty trademarked canine vaccines, and as many for cats. It is possible to vaccinate animals against thirty diseases and counting. In 1998, vaccination specialist Dr. Richard B. Ford warned, “Most of these vaccines are so useless as to be called ‘vaccines in search of diseases.

If any FDA-approved drug like hydroxychloroquine (or ivermectin) proved effective against COVID, pharmaceutical companies would no longer be legally allowed to fast-track their billion-dollar vaccines to market under Emergency Use Authorization. Instead, vaccines would have to endure the years-long delays that have always accompanied methodical safety and efficacy testing, and that would mean less profits, more uncertainty, longer runways to market, and a disappointing end to the lucrative COVID-19 vaccine gold rush. Dr. Fauci has invested $6 billion in taxpayer lucre in the Moderna vaccine alone. His agency is co-owner of the patent and stands to collect a fortune in royalties. At least four of Fauci’s hand-picked deputies are in line to collect royalties of $150,000/year based on Moderna’s success, and that’s on top of the salaries already paid by the American public.

But since the mid-1990s, pharmaceutical giants have aggressively marketed painkillers to a wider group of patients with long-term or milder forms of pain. At the same time, the federal government has approved one massive increase after another in the quantities manufactured, even as its own officials declared prescription drug abuse a mounting epidemic.

Due to commercials and the “education” of prescribers directly by pharmaceutical representatives, the idea that people who were sad and depressed had chemical imbalances in their brains became common parlance. So how is this an example of manufacturing a disease? There is no such thing as a chemical imbalance that is known to cause some identifiable disease called depression. In fact, leaders within psychiatry have called the chemical imbalance theory an “urban legend” that was never taken seriously by “well-informed psychiatrists” (Pies, 2011). An entire society was led to believe in a disease known to be caused by neurochemical imbalances as a direct result of a genius marketing scheme, and nothing more (see also Schultz & Hunter, 2016 for a review).

It is a well-known fact, and one that has given much ground for complaint, that after women have lost their genital function their character often undergoes a peculiar alteration, they become quarrelsome, vexatious and overbearing, petty and stingy, that is to say that they exhibit typically sadistic and anal-erotic traits which they did not possess earlier during their period of womanliness,” Sigmund Freud declared in 1913.8 Well, you can argue that he was a man of his time; the first couple of decades of the twentieth century weren’t exactly known for their respect for women’s finer qualities. But unfortunately, the nonsense didn’t stop there. “The unpalatable truth must be faced that all postmenopausal women are castrates,” pronounced American gynecologist Robert Wilson in a 1963 essay;9 he then elaborated fulsomely on this theme in his 1966 bestseller Feminine Forever.10 This frighteningly influential book, it later emerged, was backed by a pharmaceutical company eager to market hormone replacement therapy. “Once the ovaries stop, the very essence of being a woman stops,” psychiatrist David Reuben wrote in 1969 in another bestseller, Everything You Always Wanted to Know About Sex but Were Afraid to Ask.11 The postmenopausal woman, he added, comes “as close as she can to being a man.” Or rather, “not really a man but no longer a functional woman.” Half a century on, has anything really changed? Sadly, I don’t think so. It might not be acceptable in most circles to write that kind of thing anymore, but menopausal women are too often the butt of men’s jokes for me really to believe that the attitudes themselves have shifted. They’ve just gone a little more underground. So if these are the stories men are telling about us, where are the stories we’re telling about ourselves? Unfortunately, they’re not always very much more helpful. A surprising number of self-help or quasi-medical books by female authors toe the male line, enjoining women to try to stay young and beautiful at all costs, and head off to their doctor to get hormone replacement therapy to hold off the “symptoms” of the dreaded aging “disease” for as long as possible. Their aim, it seems, is above all a suspension of the aging process, an exhortation to live in a state of suspended animation. And although more women are beginning to write about menopause as a natural and profoundly transformational life-passage, in the culture at large it is still primarily viewed as something to be managed, held off, even fought.

Pharmaceutical companies were not content to hawk medications; they were also marketing psychological disorders themselves

Pharmaceutical companies were not content to hawk medications; they were also marketing psychological disorders themselves.

During an interview with Diversity Inc.’s director of research and product development, she walked me through a typical presentation used to pitch the value of the company’s software to prospective clients. I learned that their products are especially valuable to those industries not allowed to collect ethno-racial data directly from individuals because of civil rights legislation that attempts to curb how these data are used to discriminate. But now those who work in finance, housing, and healthcare can use predictive software programs to ascertain information that they cannot request directly. The US Health Insurance Portability and Accountability Act (HIPAA) privacy rule, for example, strictly monitors the collection, storage, and communication of individuals’ “protected health information,” among other features of the law. This means that pharmaceutical companies, which market to different groups, need indirect methods to create customer profiles, because they cannot collect racial-ethnic data directly. This is where Diversity Inc. comes in. Its software programs target customers not only on the basis of race and ethnicity, but also on the basis of socioeconomic status, gender, and a growing list of other attributes. However, the company does not refer to “race” anywhere in their product descriptions. Everything is based on individuals’ names, we are told. “A person’s name is data,” according to the director of research and product development. She explains that her clients typically supply Diversity Inc. with a database of client names and her team builds knowledge around it. The process, she says, has a 96 percent accuracy rate, because so many last names are not shared across racial–ethnic groups – a phenomenon sociologists call “cultural segregation.”18

many of these trials are not investigating novel treatments that patients might hope will save their lives, but rather “me-too” drugs which are copycats of existing medications. It is much cheaper for pharmaceutical manufacturers to bring me-too drugs to market, apply for new patents, heavily market the drugs as the “latest and greatest”, and let the money roll in.[64] Novel drug development is much costlier and riskier — and therefore far less common.

Another antiviral drug developed by Dr. Fauci’s shop, remdesivir, provides a recent example of a similar Pharma money-making scheme facilitated by NIAID/NIH. While remdesivir proved worthless against COVID, Dr. Fauci altered the study protocols to give his pet drug the illusion of efficacy.30, 31 Despite opposition from FDA and WHO, Dr. Fauci declared from the White House that remdesivir “will be the standard of care” for COVID, guaranteeing the company a massive global market. Dr. Fauci then overlooked Gilead’s price gouging; the company sold remdesivir for $3,300–$5,000 per dose, during the COVID pandemic. The raw materials to make remdesivir cost Gilead under $10. Medicaid must, by law, cover all FDA-approved drugs, so taxpayers again foot the bill. Through these boondoggles, Anthony Fauci has made himself the leading angel investor of the pharmaceutical industry.

This book is a compilation of interesting ideas that have strongly influenced my thoughts and I want to share them in a compressed form. That ideas can change your worldview and bring inspiration and the excitement of discovering something new. The emphasis is not on the technology because it is constantly changing. It is much more difficult to change the accompanying circumstances that affect the way technological solutions are realized. The chef did not invent salt, pepper and other spices. He just chooses good ingredients and uses them skilfully, so others can enjoy his art. If I’ve been successful, the book creates a new perspective for which the selection of ingredients is important, as well as the way they are smoothly and efficiently arranged together. In the first part of the book, we follow the natural flow needed to create the stimulating environment necessary for the survival of a modern company. It begins with challenges that corporations are facing, changes they are, more or less successfully, trying to make, and the culture they are trying to establish. After that, we discuss how to be creative, as well as what to look for in the innovation process. The book continues with a chapter that talks about importance of inclusion and purpose. This idea of inclusion – across ages, genders, geographies, cultures, sexual orientation, and all the other areas in which new ways of thinking can manifest – is essential for solving new problems as well as integral in finding new solutions to old problems. Purpose motivates people for reaching their full potential. This is The second and third parts of the book describes the areas that are important to support what is expressed in the first part. A flexible organization is based on IT alignment with business strategy. As a result of acceleration in the rate of innovation and technological changes, markets evolve rapidly, products’ life cycles get shorter and innovation becomes the main source of competitive advantage. Business Process Management (BPM) goes from task-based automation, to process-based automation, so automating a number of tasks in a process, and then to functional automation across multiple processes andeven moves towards automation at the business ecosystem level. Analytics brought us information and insight; AI turns that insight into superhuman knowledge and real-time action, unleashing new business models, new ways to build, dream, and experience the world, and new geniuses to advance humanity faster than ever before. Companies and industries are transforming our everyday experiences and the services we depend upon, from self-driving cars, to healthcare, to personal assistants. It is a central tenet for the disruptive changes of the 4th Industrial Revolution; a revolution that will likely challenge our ideas about what it means to be a human and just might be more transformative than any other industrial revolution we have seen yet. Another important disruptor is the blockchain - a distributed decentralized digital ledger of transactions with the promise of liberating information and making the economy more democratic. You no longer need to trust anyone but an algorithm. It brings reliability, transparency, and security to all manner of data exchanges: financial transactions, contractual and legal agreements, changes of ownership, and certifications. A quantum computer can simulate efficiently any physical process that occurs in Nature. Potential (long-term) applications include pharmaceuticals, solar power collection, efficient power transmission, catalysts for nitrogen fixation, carbon capture, etc. Perhaps we can build quantum algorithms for improving computational tasks within artificial intelligence, including sub-fields like machine learning. Perhaps a quantum deep learning network can be trained more efficiently, e.g. using a smaller training set. This is still in conceptual research domain.

Syridex Bio was founded on the belief that everyone deserves the opportunity to live a healthy life. For too long, deep inequities have persisted across our pharmaceutical, biotechnology, and medical systems. Despite increased public attention on the problem in recent years, progress remains far too slow. At Syridex Bio, we are addressing this gap in the market by strategically investing in therapies that treat diseases disproportionately affecting underserved communities. By financing the development of drugs and treatments addressing the world’s greatest health disparities, we are convinced that we can accelerate health equity globally and achieve strong financial returns for our investors.

you are being different just for the sake of being different, you can always come down in the morning with a sock in your mouth.' When you are strategically creative, everything you say or do is different but also meets a predetermined purpose.

In universities and pharmaceutical labs around the world, computer scientists and computational biologists are designing algorithms to sift through billions of gene sequences, looking for links between certain genetic markers and diseases. The goal is to help us sidestep the diseases we're most likely to contract and to provide each one of us with a cabinet of personalized medicines. Each one should include just the right dosage and the ideal mix of molecules for our bodies. Between these two branches of research, genetic and behavioral, we're being parsed, inside and out. Even the language of the two fields is similar. In a nod to geneticists, Dishman and his team are working to catalog what they call our "behavioral markers." The math is also about the same. Whether they're scrutinizing our strands of DNA or our nightly trips to the bathroom, statisticians are searching for norms, correlations, and anomalies. Dishman prefers his behavioral approach, in part because the market's less crowded. "There are a zillion people looking at biology," he says, "and too few looking at behavior." His gadgets also have an edge because they can provide basic alerts from day one. The technology indicating whether a person gets out of bed, for example, isn't much more complicated than the sensor that automatically opens a supermarket door. But that nugget of information is valuable. Once we start installing these sensors, and the electronics companies get their foot in the door, the experts can start refining the analysis from simple alerts to sophisticated predictions-perhaps preparing us for the onset of Parkinson's disease or Alzheimer's.

In universities and pharmaceutical labs around the world, computer scientists and computational biologists are designing algorithms to sift through billions of gene sequences, looking for links between certain genetic markers and diseases. The goal is to help us sidestep the diseases we're most likely to contract and to provide each one of us with a cabinet of personalized medicines. Each one should include just the right dosage and the ideal mix of molecules for our bodies. Between these two branches of research, genetic and behavioral, we're being parsed, inside and out. Even the language of the two fields is similar. In a nod to geneticists, Dishman and his team are working to catalog what they call our "behavioral markers." The math is also about the same. Whether they're scrutinizing our strands of DNA or our nightly trips to the bathroom, statisticians are searching for norms, correlations, and anomalies. Dishman prefers his behavioral approach, in part because the market's less crowded. "There are a zillion people looking at biology," he says, "and too few looking at behavior." His gadgets also have an edge because they can provide basic alerts from day one. The technology indicating whether a person gets out of bed, for example, isn't much more complicated than the sensor that automatically opens a supermarket door. But that nugget of information is valuable. Once we start installing these sensors, and the electronics companies get their foot in the door, the experts can start refining the analysis from simple alerts to sophisticated predictions-perhaps preparing us for the onset of Parkinson's disease or Alzheimer's.

ON SEPTEMBER 2, 2009, THE TRANSNATIONAL PHARMACEUTICAL GIANT Pfizer pled guilty to multiple criminal felonies. It had been marketing drugs in a way that may well have led to the deaths of people and that definitely led physicians to prescribe and patients to use pharmaceuticals in ways they were not intended.

Almost all the scientific studies Irving had looked at up to now, the e-mail explained, had a catch. The vast majority of research into whether drugs work or not is funded by big pharmaceutical companies, and they do this research for a specific reason: they want to be able to market those drugs so they can make a profit out of them. That’s why the drug companies conduct their scientific studies in secret, and afterward, they only publish the results that make their drugs look good, or that make their rivals’ drugs look worse. They do this for exactly the same reasons that (say) KFC would never release information telling you that fried chicken isn’t good for you.

One of the most studied ideas as to what causes schizophrenia is the 'chemical imbalance theory,' which derives psychiatric pharmaceuticals themselves. Though the 'mechanism of action' of drugs marketed for their 'antipsychotic' properties isn't understood--plainly, drug companies believe these drugs are effective in lessening psychiatric symptoms, but they don't actually know why--what is known is that they affect chemical levels in the brain. It's therefore supposed that abnormal chemical levels might somehow be crucial to understanding what's different about the brains of people diagnosed with schizophrenia. Testing chemical levels inside brains remains impossible. Despite billions of dollars of investigation, the chemical imbalance theory has never been confirmed.

our thing run has made to address the issues of the market and remain mindful of everything regarding the most recent change. Chiller Manufacturer in Delhi have been showing up, making and appropriating high bore and influencing things that are utilized more than a couple of sets out to cool water or fluid for both mechanical and business applications, making us a director among the most kept up chiller makers India. The thing run contains air and water-cooled scroll chillers, air and water-cooled screw chillers. Within excess of three diverse expansive stretches of experience added to our accumulation, we are hailed as one of the genuine chiller makers in the nation. As chiller creators we consider the solace cooling/cooling division and we other than consider mechanical cooling process applications over a system of undertakings including: sustenance, drink, plastic, substance, pharmaceutical, atomic power, repairing and fresh sparing. All through the most recent three decades, we have gotten from our experience and got quality in both solace cooling and mechanical cooling spaces. Chiller Manufacturer in Delhi for the most part repair our things to keep up to the most recent change to give the most strong, solid and competent things to our watching purchasers. Picking the best and most confided in Chiller Manufacturer in Delhi is fundamental as this will pick the cut off that your unit accomplishes. Since there are such a fundamental number of in the nation, it is dejected upon you to pull back the best from the rest and see your call. At chiller creator in Delhi, the consideration is on buyer unflinching quality and building machines that are outrageous, solid and offer noteworthy association. You can rely on us for the best levels of relationship, until the moment that the minute that your technique is made, and after, when you need help, absolutely at whatever point. Every single one of our machines have been spread out and made, holding fast to client necessities and utilizing the most recent movement, with the target that you can get the best quality for your business. We recognize that our obligation in this little way, can take your business to exceptional statures. Consequently, turn around picking the plain best, and you won't be astounded.

Racetams are some of the best studied and the oldest cognitive-enhancing pharmaceuticals on the planet, and they have very few side effects. The first of this class of very safe drugs is called piracetam, and I took it for a few years before switching to more recently evolved versions. Four different well-constructed studies show that piracetam improves mitochondrial function.19 In fact, I believe this may be one of its important mechanisms of action, one that is overlooked in most of its descriptions. This is one of the safest pharmaceuticals on the market, and it makes your brain and your mitochondria work better. I recommend two forms of this drug that

One memo from this marketing firm read “draft completed. we just need an author.

It takes about twelve years for a pharmaceutical firm to research, develop, test, and launch a product. Several firms, including Pfizer, Novartis, and Celgene, are working with IBM Watson to try to identify and bring new drugs to market faster.

The vast majority of research into whether drugs work or not is funded by big pharmaceutical companies, and they do this research for a specific reason: they want to be able to market those drugs so they can make a profit out of them.

When a doctor proclaims that the vaccines they advocate are evidenced-based, you are witnessing one of the most disturbing frauds in history. As we have said previously, doctors are among the worst people in the world to comment on vaccines.442 They usually recommend them even though they have not studied the nature of the disease, the historical data including when the vaccine was introduced, and what is actually in the vials. When an adverse event occurs there is typically a cognitive dissonance for the vaccine promoter who does their bit to maintain the “safe and effective” mantra, not realizing that it is a marketing slogan invented by the pharmaceutical industry.

In the nineteenth century the global economy was worth a little more than $1 trillion, in today’s money. That means each year capital needed to find new investments worth about $30 billion – a significant sum. This required a huge effort on the part of capital, including the colonial expansion that characterised the nineteenth century. Today the global economy is worth over $80 trillion, so to maintain an acceptable rate of growth capital needs to find outlets for new investments worth another $2.5 trillion next year. That’s the size of the entire British economy – one of the biggest in the world. Somehow we have to add the equivalent of another British economy next year, on top of what we are already doing, and then add even more than that the following year, and so on. Where can this quantity of growth possibly be found? The pressures become enormous. It’s what is driving the pharmaceutical companies behind the opioid crisis in the United States; the beef companies that are burning down the Amazon; the arms companies that lobby against gun control; the oil companies that bankroll climate denialism; and the retail firms that are invading our lives with ever-more sophisticated advertising techniques to get us to buy things we don’t actually want. These are not ‘bad apples’ – they are obeying the iron law of capital. Over the past 500 years, an entire infrastructure has been created to facilitate the expansion of capital: limited liability, corporate personhood, stock markets, shareholder value rules, fractional reserve banking, credit ratings – we live in a world that’s increasingly organised around the imperatives of accumulation.

By 2020, the revenue of the global pharmaceutical market was US$1.27 trillion, of which the North American market share was 48.7 percent. The EU has a 14 percent share.4 African nations, which were suffering the worst of the HIV epidemic, accounted for 0.7 percent of the global pharmaceutical market. Despite being the worst affected, the African continent remained on the sidelines during the first two decades of the HIV response.